CMA again accuses Advanz of pharma collusion

The UK’s competition watchdog has issued a fourth statement of objections against Advanz Pharma, now accusing the drugmaker and two others of carving up the market for the antibiotic Nitrofurantoin.


Get unlimited access to all Global Competition Review content